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Abstract To study the role of the catalytic domain in v-Src
substrate specificity, we engineered three site-directed mutants
(Leu-472 to Tyr or Trp and Thr-429 to Met). The mutant forms
of Src were expressed in Sf9 cells and purified. We analyzed the
substrate specificities of wild-type v-Src and the mutants using
two series of peptides that varied at residues C-terminal to
tyrosine. The peptides contained either the YMTM motif found
in insulin receptor substrate-1 (IRS-1) or the YGEF motif
identified from peptide library experiments to be the optimal
sequence for Src. Mutations at positions Leu-472 or Thr-429
caused changes in substrate specificity at positions P+1 and P+3
(i.e. one or three residues C-terminal to tyrosine). This was
particularly evident in the case of the L-472W mutant, which had
pronounced alterations in its preferences at the P+1 position.
The results suggest that residue Leu-472 plays a role in P+1
substrate recognition by Src. We discuss the results in the light of
recent work on the roles of the SH2, SH3 and catalytic domains
of Src in substrate specificity.
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1. Introduction
c-Src is a cytoplasmic tyrosine kinase that is widely ex-
pressed in mammalian tissues. c-Src participates in signal
transduction pathways that transmit extracellular signals
across the cell membrane to the cytoplasm and nucleus (re-
viewed in [1]). v-Src, the viral homolog of c-Src, is the protein
product of the transforming gene from Rous sarcoma virus.
Src kinases are composed of an N-terminal membrane binding
region, a unique domain, an SH3 domain that binds proline-
rich sequences, a phosphotyrosine binding SH2 domain, a
tyrosine kinase catalytic domain and a C-terminal tail, which
is closely involved in the negative regulation of kinase activity
[2,3].
The recent crystal structures of the inactive forms of Src
and Hck, a Src-family kinase, reveal that intramolecular in-
teractions involving the SH3 and SH2 domains inhibit kinase
activity [4,5]. A polyproline type II helix is present in the
linker connecting the SH2 domain to the catalytic domain.
This linker acts as a docking site for the SH3 domain. This
SH3-PPII linker interaction appears to inhibit kinase activity
by stabilizing an inactive conformation of the catalytic do-
main [4^6]. Binding of the SH2 domain to the phosphorylated
C-terminal tail also contributes to enzyme inhibition [1^6].
In addition to their inhibitory roles, the SH2 and SH3 do-
mains of Src-family kinases have been shown to mediate bind-
ing of Src to other proteins, including some of its substrates.
For example, Src and Abl tyrosine kinases preferentially phos-
phorylate peptides that are suited to bind their own SH2
domains [7]. The presence of a high-a⁄nity SH2 binding
site in a peptide substrate results in a dramatic increase in
the phosphorylation rate of additional tyrosines in the peptide
[8]. Replacement of the Abl SH2 domain with other SH2
domains led to a change in substrate speci¢city in vivo [9].
These results suggest that the SH2 domains of intracellular
kinases may be involved in substrate recognition.
At present, the role of the catalytic domains of tyrosine
kinases in determining target speci¢city is not fully under-
stood. The crystal structure of the insulin receptor complexed
with peptide substrate highlights speci¢c interactions with res-
idues surrounding tyrosine in the substrate [10]. Such interac-
tions could contribute to substrate speci¢city for other tyro-
sine kinases as well. This is illustrated by studies of the RET
receptor protein kinase. Wild-type RET receptor tyrosine kin-
ase has a methionine residue at position 918, whereas cyto-
plasmic tyrosine kinases have threonine at the corresponding
position. A naturally occurring Met-918CThr mutation in
the RET receptor is associated with multiple endocrine neo-
plasia type 2B [11,12]. This variant of the kinase preferentially
phosphorylates optimal substrates for Src and Abl, whereas
wild-type RET protein preferentially phosphorylates the opti-
mal peptide substrates for EGF receptor [7]. This result high-
lights the importance of the catalytic domain in tyrosine kin-
ase signaling. Taken together with studies of the SH2 domains
described above, it appears that the catalytic and SH2 do-
mains provide a double selection to maintain the ¢delity of
signaling events. In this paper, we describe experiments aimed
at understanding the contribution of the Src catalytic domain
itself in substrate speci¢city.
Previously, we generated site-directed mutants of the Abl
catalytic domain that showed distinct changes in substrate
speci¢city relative to wild-type Abl [13]. In this paper, we
have applied a similar protein engineering approach to v-Src
kinase to study the enzyme’s substrate speci¢city. Based on
the results with site-directed mutants of Abl, we have engi-
neered three mutant forms of v-Src kinase to investigate
changes in substrate speci¢city. We assayed the e¡ects of mu-
tagenesis using synthetic peptide substrates. Synthetic peptides
derived from the insulin receptor kinase substrate-1 (IRS-1)
containing Tyr-Met-X-Met (YMXM) motifs are good sub-
strates for v-Src and v-Abl[14]. Moreover, these non-receptor
tyrosine kinases show distinct speci¢cities towards the
YMXM motif peptides. Another excellent substrate for Src
is a synthetic peptide possessing the sequence AEEEIYGE-
FEAKKKK (YGEF motif) that was identi¢ed in peptide li-
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brary experiments [7]. Therefore, we prepared two series of
peptides containing variations in the YMXM and YGEF mo-
tifs to examine the substrate speci¢cities of our engineered
mutant forms of v-Src.
2. Materials and methods
2.1. v-Src expression plasmid
v-Src DNA from the Schmidt-Ruppin strain of Rous sarcoma virus
(encoding amino acids 77^526, comprising the SH3, SH2 and catalytic
domains of v-Src) was subcloned from a pGeU2T-SH3-SH2-catalytic
domain plasmid [15] into pFastBacHTb (Gibco BRL) as a BamHI/
EcoRI fragment.
2.2. Mutagenesis, expression in Sf9 cells and puri¢cation of v-Src
We carried out site-directed mutagenesis using the Quikchange Mu-
tagenesis System from Stratagene. For each mutation, the pFast-
BacHTb-Src plasmid and two synthetic oligonucleotides containing
the desired mutation in v-Src kinase were used. The DNA sequences
encoding the catalytic domains of mutant forms of v-Src were con-
¢rmed by DNA sequencing.
Wild-type and mutant forms of v-Src were expressed in Spodoptera
frugiperda (Sf9) cells. 0.5 l of Sf9 cells (1.5U106 cells/ml) was infected
with recombinant v-Src baculovirus and cells were harvested 3 days
after infection for protein puri¢cation. Cells were washed with phos-
phate-bu¡ered saline and lysed in a French pressure cell two times, in
bu¡er containing 10 mM Tris-HCl (pH 8.5), 50 mM sodium £uoride,
0.2 mM sodium vanadate, 1% NP-40, 5 Wg/ml leupeptin, 5 Wg/ml
aprotinin and 2 mM phenylmethylsulfonyl £uoride. After centrifuga-
tion at 10 000Ug for 30 min, the supernatant was applied to a hy-
droxyapatite column (2.5U3 cm) which was pre-equilibrated with
homogenization bu¡er. Src kinases were eluted by a gradient of po-
tassium phosphate (0^0.4 M) in homogenization bu¡er. Src activity
was measured with KKEEEEIYMMMM (E4IYM4) as a peptide sub-
strate and fractions containing Src activity were pooled and dialyzed
against 20 mM Tris-HCl (pH 8.5), 500 mM KCl, 5 mM 2-mercapto-
ethanol, 20 mM imidazole and 10% glycerol. After dialysis, fractions
were applied to a Ni-NTA column (bed volume 3 ml, Qiagen) which
was pre-equilibrated with 20 mM Tris-HCl (pH 8.5), 100 mM KCl,
5 mM 2-mercaptoethanol, 20 mM imidazole and 10% glycerol. Src
kinases were eluted by 20 mM Tris-HCl (pH 8.5), 100 mM KCl,
100 mM imidazole, 5 mM 2-mercaptoethanol and 10% glycerol.
2.3. Peptide synthesis and characterization
Peptide substrates were synthesized on an Applied Biosystems au-
tomated peptide synthesizer using standard Fmoc chemistry [16]. Pep-
tides were puri¢ed by reversed-phase high performance liquid chro-
matography and characterized by matrix-assisted laser description/
ionization time of £ight mass spectrometry. Quantitative amino acid
analysis (Commonwealth Biotechnologies) was used to determine the
concentration of peptide stock solutions.
2.4. Kinase assays using synthetic peptide substrates
Kinase activity was measured in two ways: (1) using the phospho-
cellulose binding assay [17] or (2) a continuous spectrophotometric
assay [18]. For initial comparisons of substrate speci¢city using the
phosphocellulose binding assay, the reaction mixtures contained 20
mM Tris-HCl (pH 7.4), 10 mM MgCl2, 0.1 mM Na3VO4, 0.25 mM
ATP, 0.5 mM peptide substrate and [Q-32P]ATP (100^200 cpm/pmol).
Reactions were initiated by addition of Src. After a 30 min incubation
at 30‡C, reactions were stopped and spotted on phosphocellulose
paper. Incorporation of 32P into peptide was determined by liquid
scintillation counting. A continuous spectrophotometric assay [18]
was used for a more detailed kinetic analysis. Reactions were carried
out at 30‡C in volumes of 500 Wl containing 20 mM Tris-HCl (pH
7.4), 10 mM MgCl2, 0.25 mM ATP, 1 mM phosphoenolpyruvate,
1 mg K-nicotinamide adenine dinucleotide reduced form, pyruvate
kinase (42 U), lactate dehydrogenase (60 U) and various concentra-
tions of peptides (60^2000 WM). Reactions were initiated by the addi-
tion of Src or Src mutants. Data were collected every 30 s to deter-
mine initial rates of peptide phosphorylation.
3. Results and discussion
3.1. Src residues targeted for mutagenesis
In a previous report from this laboratory, mutation of sev-
en residues in c-Abl caused changes in substrate speci¢city,
especially in the recognition of the P31, P+1 and P+3 posi-
tions of bound peptide substrates [13]. (Amino acids in pro-
tein kinase substrates are numbered relative to P, the phos-
phorylated residue). Src and Abl display di¡erences in
substrate speci¢city at the P+1 and P+3 positions. Based on
the known three-dimensional structure of Src [4] and by anal-
ogy to our results for Abl [13], we selected Leu-472 as a
residue that might be involved in P+3 substrate recognition.
We constructed two mutations at this position: Leu-472 to
Trp (L-472W), because a Trp residue at this position in Abl
altered P+3 speci¢city [13], and Leu-472 to Tyr (L-472Y), the
corresponding residue in wild-type Abl. We note that amino
acids near the putative P+1/P+3 pocket in the Hck and Src
structures are conserved [4,5], supporting the idea that local
perturbations in structure will have a predictable e¡ect on
speci¢city. A naturally occurring mutation of the kinase do-
main of RET receptor (Met-918CThr) showed alterations in
P+1 position substrate recognition [7,11,12]. Therefore, we
prepared a Src mutant in which the corresponding amino
acid (Thr-429) was changed to Met, the residue found in
receptor tyrosine kinases. We expected that this mutation
might a¡ect substrate recognition at the P+1 position. The
positions in v-Src that were mutated are shown in Fig. 1.
3.2. Expression of wild and mutant forms of v-Src in Sf9 cells
The Src construct used in this study contained the SH3,
SH2 and catalytic domains. Wild-type and mutant forms of
Src from baculovirus-infected Sf9 cells were puri¢ed by a hy-
Fig. 1. Ribbon representation of the Src tyrosine kinase catalytic
domain structure [4]. The residues that we mutated are shown in
ball and stick format. The ¢gure was generated from the atomic co-
ordinates using the program MOLSCRIPT [19].
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droxyapatite column followed by a Ni-NTA column. (Initial
attempts to use Ni-NTA as a single step puri¢cation yielded
insu⁄ciently pure preparations of enzymes). The proteins
were more than 95% pure, as judged by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis and Coomassie bril-
liant blue staining. The proteins also displayed immunoreac-
tivity towards anti-c-Src antibody (results not shown).
3.3. Comparison of wild-type and mutant forms of v-Src with
IRS-1 (YMXM) and YGEF peptides
Previously, we demonstrated that peptides containing
YMXM motifs derived from IRS-1 are good substrates for
v-Src and c-Abl [14]. For initial comparative experiments, we
compared the in vitro substrate speci¢cities of the wild-type
and mutant forms of v-Src using a series of IRS-1 synthetic
peptides containing YMXM motifs (Table 1). These peptides
were based on the sequence of IRS-1 surrounding Tyr-987
(SRGDYMTMQ) with single amino acid substitutions at
the P+1/P+3 positions. For insulin receptor, these phospho-
rylated YMTM motifs act as docking sites for downstream
signalling proteins containing SH2 domains [20]. As shown in
Fig. 2, IRS-1 peptides are substrates for the mutant forms of
Src, although the speci¢c activities of the Src mutants towards
these peptides were typically W10 times lower than that of
wild-type v-Src. Nonetheless, some di¡erences in substrate
speci¢city were apparent. Wild-type v-Src showed the highest
speci¢c activity towards peptides containing substitutions at
the P+1 position such as YATM, YETM and YNleTM,
whereas peptides containing substitutions at the P+3 position
such as YMTT and YMTP showed much lower speci¢c activ-
ities. The L-472Y mutant preferred Nle or Ile at the P+1
Table 1
Peptide sequences used in this study
1. Sequences derived from IRS-1 Tyr-987
YMTM Lys-Lys-Ser-Arg-Gly-Asp-Tyr-Met-Thr-Met-Gln-Ile-Gly
YNleTM Lys-Lys-Ser-Arg-Gly-Asp-Tyr-Nle-Thr-Met-Gln-Ile-Gly
YETM Lys-Lys-Ser-Arg-Gly-Asp-Tyr-Glu-Thr-Met-Gln-Ile-Gly
YITM Lys-Lys-Ser-Arg-Gly-Asp-Tyr-Ile-Thr-Met-Gln-Ile-Gly
YATM Lys-Lys-Ser-Arg-Gly-Asp-Tyr-Ala-Thr-Met-Gln-Ile-Gly
YMTA Lys-Lys-Ser-Arg-Gly-Asp-Tyr-Met-Thr-Ala-Gln-Ile-Gly
YMTP Lys-Lys-Ser-Arg-Gly-Asp-Tyr-Met-Thr-Pro-Gln-Ile-Gly
YMTT Lys-Lys-Ser-Arg-Gly-Asp-Tyr-Met-Thr-Thr-Gln-Ile-Gly
2. Sequences derived from Src optimal phosphorylation motif
YGEF Ala-Glu-Glu-Glu-Ile-Tyr-Gly-Glu-Phe-Glu-Ala-KKKKG
YAEF Ala-Glu-Glu-Glu-Ile-Tyr-Ala-Glu-Phe-Glu-Ala-KKKKG
YMEF Ala-Glu-Glu-Glu-Ile-Tyr-Met-Glu-Phe-Glu-Ala-KKKKG
YGET Ala-Glu-Glu-Glu-Ile-Tyr-Gly-Glu-Thr-Glu-Ala-KKKKG
YGEA Ala-Glu-Glu-Glu-Ile-Tyr-Gly-Glu-Ala-Glu-Ala-KKKKG
YGEM Ala-Glu-Glu-Glu-Ile-Tyr-Gly-Glu-Met-Glu-Ala-KKKKG
3. Other sequences
E4YM4 Lys-Lys-Glu-Glu-Glu-Glu-Tyr-Met-Met-Met-Met
E4IYM4 Lys-Lys-Glu-Glu-Glu-Glu-Ile-Tyr-Met-Met-Met-Met
The names used in the text are given in the left-hand column. The
phosphorylated tyrosine residues are in bold. The underlined resi-
dues are changes from the parent sequences. KKKKG = Lys-Lys-
Lys-Lys-Gly. Nle = norleucine.
Fig. 2. Phosphorylation of IRS-1 peptides by wild-type and three mutant forms of v-Src (T-429M, L-472W and L-472Y). The Src kinase activ-
ities were determined after 30 min incubation at 30‡C using the phosphocellulose binding assay [17]. The peptide concentration in the assay
was 0.5 mM. The unit of speci¢c activity is pmol of phosphate incorporated/min/Wg protein. The sequences of the peptides are given in Table 1.
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position, but a peptide containing Glu at the P+1 position
was a poor substrate (Fig. 2). The L-472W form of Src pre-
ferred YATM and YNleTM substituted peptides. The T-
429M mutant preferred a peptide containing Thr at the P+3
position (YMTT), although this sequence was not recognized
well by wild-type Src or the other mutants. These data sug-
gested that mutations at residues Leu-472 or Thr-429 of Src
caused changes in recognition of the P+1/P+3 positions in
bound peptide substrates. Src is more tolerant of substitutions
at the P+1 position of YMXM-containing substrates than
insulin receptor, another kinase that has been examined in
detail with regard to phosphorylation of YMXM peptides
[21]. This may explain why the changes we observed in sub-
strate speci¢city were subtle and were re£ected in changes in
the rank order of speci¢c activities (Fig. 2), rather than in
complete changes in the overall speci¢city.
To examine changes in substrate speci¢city in a di¡erent
peptide context, we synthesized another series of peptides
based on the parent sequence, AEEEIYGEFEAKKKK.
This peptide contains YGEF, the optimal Src phosphoryla-
tion sequence C-terminal to tyrosine that was identi¢ed in
peptide library studies [7]. We designed peptides with substi-
tutions at the P+1 and P+3 positions of YGEF based on our
results from the IRS-1 peptides (Table 1). As shown in Fig. 3,
in initial screens of activity, YGEF and its derivatives dis-
played much higher speci¢c activities for all v-Src kinases
than the IRS-1-derived peptides. For wild-type Src, the spe-
ci¢c activity of the best YGEF peptide was W35 times higher
than the best YMTM peptides (compare Figs. 2 and 3). Sub-
stitutions of Ala or Met at the P+1 position in the YGEF
motif resulted in higher speci¢c activities for wild-type and
mutant forms of v-Src. This e¡ect was especially pronounced
for the L-472W mutant of Src, where substitution of Met or
Ala at the P+1 position increased the speci¢c activity 29- or
22-fold, respectively, relative to YGEF (Fig. 3). The other
mutants (L-472Y and T-429M) also showed a more dramatic
di¡erence between the YMEF/YAEF peptides and the YGEF
peptide than wild-type Src did (Fig. 3). KKEEEEYMMMM
(E4YM4), the optimal peptide substrate predicted for insulin
receptor [7], was a poorer substrate for all v-Src kinases (Fig.
3). Taken together, the data suggested that mutations of Thr-
429 and particularly of Leu-472 cause alterations in substrate
preference at the P+1 position.
3.4. Kinetic parameters of the phosphorylation of
YGEF-containing peptide substrates by wild-type
and mutant forms of v-Src
To further investigate the substrate speci¢city of wild-type
Src and the mutants, kinetic analysis was carried out using
YGEF peptides with substitutions at the P+1 or P+3 posi-
tions (YGEF, YAEF, YMEF and YGET) (Table 2). An addi-
tional peptide, KKEEEEIYMMMM (E4IYM4), was also
tested. This peptide is unrelated in sequence to the YGEF
substrates at positions N-terminal to tyrosine, but possesses
Fig. 3. Phosphorylation of YGEF peptides by wild-type and three mutant forms of v-Src (T-429M, L-472W and L-472Y). The activities of
wild-type and mutant forms of Src were determined using a peptide concentration of 0.5 mM after 30 min incubation at 30‡C. Data were ob-
tained using the phosphocellulose binding assay [17]. The unit of speci¢c activity is pmol of phosphate incorporated/min/Wg protein. The se-
quences of the peptides are given in Table 1.
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an optimal Src phosphorylation sequence at these positions
[7,22]. In terms of Km and Vmax, YGEF is the best substrate
for wild-type v-Src (Km = 98 WM and Vmax = 120.3 Wmol/min/
mg) and for the L-472Y mutant (Km = 65 WM and Vmax = 3.4
Wmol/min/mg). In contrast, the L-472W mutant phosphory-
lated the P+1 Ala peptide (YAEF) best with Km = 100 WM
and a Vmax/Km value of 30.0. The L-472W mutant also pre-
ferred YMEF (Vmax/Km = 23.6) over the parent YGEF peptide
(Vmax/Km = 12.0). As seen in Table 2, these e¡ects were most
pronounced in the increases in Vmax for the Ala/Met substi-
tutions at the P+1 position. Thus, as observed in the initial
screens (Fig. 3), the Leu-472 to Trp mutation in v-Src altered
the preference at the P+1 position from Gly to Ala or Met.
The T-429M mutant showed a low Km value (53 WM) and
high Vmax (1.8 Wmol/min/mg) towards YGEF and substitution
of Gly with Ala in peptide YAEF resulted in a signi¢cant
increase in Km (470 WM). For the T-429M mutation in v-
Src, the presence of a Thr residue at the P+3 position did
not decrease Vmax/Km as dramatically as for wild-type v-Src
and the other mutants (Table 2).
Overall, in terms of Km and Vmax/Km, YGEF is the best
substrate for wild-type as well as for the L-472Y and T-429M
mutants (Vmax/Km = 1227, 52.3 and 33.9 for wild-type, L-472Y
and T-429M, respectively), suggesting that Gly at the P+1
position of YGEF peptides participates in a speci¢c interac-
tion between the substrate and v-Src. The exception to this
overall speci¢city was the L-472W mutant form of Src. The L-
472W mutant showed a preference for Ala or Met at the P+1
position in peptide substrates. Based on results for v-Abl [13],
we expected that the L-472W mutation would primarily a¡ect
P+3 substrate recognition. A Trp mutation in the correspond-
ing position of Abl completely altered P+3 substrate recogni-
tion towards synthetic peptides as well as towards Crk, a
protein substrate possessing the ideal Abl recognition se-
quence. Thus, while this region of the Src and Abl catalytic
domains may be involved in recognition of the P+1/P+3 posi-
tions, the precise contributions of di¡erent enzyme residues
may vary between the two tyrosine kinases.
It is increasingly clear that the in vivo substrate speci¢city
of a Src-family tyrosine kinase re£ects not only the intrinsic
speci¢city of the kinase catalytic domain, but also the e¡ective
local concentrations of protein substrates. The distribution of
potential substrates is in£uenced by (a) the cellular distribu-
tion of enzyme and substrates and (b) interactions with non-
catalytic regions of the enzymes, particularly the SH2 and
SH3 domains [1]. These interactions recruit substrates to the
vicinity of the tyrosine kinase catalytic domain. The question
then arises, to what extent does the speci¢city of the catalytic
domain of a tyrosine kinase govern speci¢c signalling? An
extreme view would be that the catalytic domains are non-
speci¢c, phosphorylating any protein that is presented to them
by their associated SH2/SH3 domains. Evidence supporting
this idea comes from experiments on Abl. In these studies,
altering the Abl SH2 domain resulted in phosphorylation of
alternative substrates in vivo [8], suggesting that interactions
with non-catalytic domains play an important role in sub-
strate speci¢city. On the other hand, the catalytic domains
of tyrosine kinases have been demonstrated to have intrinsic
speci¢cities [7,14,22]. In at least one case, the intrinsic specif-
icity of a tyrosine kinase catalytic domain has been shown
to be important in signalling: the RET receptor tyrosine kin-
ase [7,11,12]. Mutants with an altered catalytic domain
speci¢city will be valuable tools in addressing the relative im-
portance of individual domains in Src kinase signalling spe-
ci¢city.
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